AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
LB Pharmaceuticals Inc Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00XNP5MR3
38.73▼ 0.69 (-1.75%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
39.42
Day's Range
38.26 – 39.73
52-Week Range
14.32 – 50.16
Volume
188.3K
Avg Volume
423.3K
Share Statistics
Shares Outstanding
Employees
27
Exchange
XNAS
Listed
2025-09-11
Share count as of August 5, 2026

LB Pharmaceuticals Inc Common Stock (LBRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about LB Pharmaceuticals Inc Common Stock (LBRX)
What is LB Pharmaceuticals Inc Common Stock's Market Cap?
LB Pharmaceuticals Inc Common Stock's Market Cap is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is LB Pharmaceuticals Inc Common Stock's Enterprise Value?
LB Pharmaceuticals Inc Common Stock's Enterprise Value is $921.6M, based on as-reported figures from SEC (XBRL) filings.
What is LB Pharmaceuticals Inc Common Stock's Net Income (TTM)?
LB Pharmaceuticals Inc Common Stock's Net Income (TTM) is -$85.7M, based on as-reported figures from SEC (XBRL) filings.
What is LB Pharmaceuticals Inc Common Stock's Diluted EPS (TTM)?
LB Pharmaceuticals Inc Common Stock's Diluted EPS (TTM) is -2.66, based on as-reported figures from SEC (XBRL) filings.
What is LB Pharmaceuticals Inc Common Stock's Net Debt?
LB Pharmaceuticals Inc Common Stock's Net Debt is -$327.8M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · LBRXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Operating expenses
Research and development
General and administrative
Total operating loss
Non-operating income
Interest income
Realized gain on sale of marketable securities, net
(Loss) gain on change in fair value of derivative instruments
Total non-operating income (loss)
Loss before income tax
Income tax provision
Net loss
Net loss per share, basic—
Net loss per share, diluted—